# Combined Food and Drug Administration and Sponsor Oncologic Drugs Advisory Committee Briefing Document - FDA Guidance Document

Source: https://www.keypedia.com/guidances/guidance-document/combined-food-and-drug-administration-and-sponsor-oncologic-drugs-advisory-committee-briefing-document/acf14472-e5b8-47ba-a5bd-76d6bae8bd27

> FDA guidance document: Combined Food and Drug Administration and Sponsor Oncologic Drugs Advisory Committee Briefing Document. Issue date: December 27, 2024. Get complete insights and analysis.

---

## Details

- Title: Combined Food and Drug Administration and Sponsor Oncologic Drugs Advisory Committee Briefing Document
- Communication Type: Guidance Document
- Product Type: biologics
- Office Name: Office of the Commissioner
- Office URL: /offices/office-of-the-commissioner/79483979-9582-427f-ac3d-46c715811424
- Issue Date: 2024-12-27
- Last Changed: 2025-01-03
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2024-D-4490">FDA-2024-D-4490</a>

## Related Documents

- [Drug Master Files Guidance for Industry](https://www.keypedia.com/guidances/guidance-document/drug-master-files-guidance-for-industry/7dfd5140-3156-43f2-bdb9-d23ad597311c)
- [Tissue Agnostic Drug Development in Oncology: Draft Guidance for Industry](https://www.keypedia.com/guidances/guidance-document/tissue-agnostic-drug-development-in-oncology-draft-guidance-for-industry/3835823e-c995-46e5-98c7-9422ad94971f)
- [Biomarker Qualification: Evidentiary Framework: Draft Guidance for Industry and FDA Staff](https://www.keypedia.com/guidances/guidance-document/biomarker-qualification-evidentiary-framework-draft-guidance-for-industry-and-fda-staff/c198796d-4230-4499-a6ee-2f84eed424c9)